Fri, Sep-28-18, 18:31
|
 |
Senior Member
Posts: 19,237
|
|
Plan: atkins, carnivore 2023
Stats: 225/224/163
BF:
Progress: 2%
Location: Massachusetts
|
|
April 10, 2018; 90 (15 Supplement) APRIL 22, 2018
Exposure-Response Analysis of Cannabidiol (CBD) Oral Solution for the Treatment of Lennox–Gastaut Syndrome (P1.271)
Gilmour Morrison, Maria Luisa Sardu, Christian Hove Rasmussen, Kenneth Sommerville, Claire Roberts, Graham E. Blakey
First published April 9, 2018,
Quote:
Results: Both dose levels showed a separation between the change from baseline of drop seizures for active treatment compared to placebo after approximately 15 days. At the 20mg/kg dose, a higher proportion of patients achieved ≥75% and 100% seizure reduction. Logistic regression analysis of the drop seizure responder rate revealed a significant (p<0.01) positive correlation with the AUC for CBD and 7-OH-CBD exposures. Predicted probability of response was in the order of 80% for the highest AUCs. For several AEs, logistic regression found a significant positive correlation between the probability of a subject having at least one AE and the respective AUC of the analytes.
Conclusions: Results suggest that the observed efficacy and safety responses are directly related to CBD and 7-OH-CBD exposure. Add-on CBD could represent a viable treatment for an otherwise pharmacoresistant condition.
|
|